Tethis launches See.d®, the first fully automated, standardized pre-analytical platform for comprehensive liquid biopsy testing
Retrieved on:
Monday, May 16, 2022
FISH, Centrifugation, Blood, Freezing, Research, Cell adhesion, AI, European Association of Urology, CFNA-FM, Patient, Microdissection, Workflow, EDTA, SBS, Association, Cell, MILAN, Efficiency, Plasma, Chinese, Industry, Liquid biopsy, MACS, Technology, Biomarker, ICC, Acquisition, Collection, Cancer, Classification, Hand, Medical imaging, Fluorescence
MILAN, May 16, 2022 /PRNewswire/ -- Tethis S.p.A announces the release of See.d®, the first universal blood sample preparator for liquid biopsy analysis. This innovative technology performs a completely automated and standardized preparation of a blood sample at the point of blood collection. Cellular fraction is gently stabilized on proprietary, nanocoated SBS slides for rare cell detection, including CTCs, while plasma is made available for the analysis of cell-free content.
Key Points:
- This innovative technology performs a completely automated and standardized preparation of a blood sample at the point of blood collection.
- See.d processes fresh blood collected in EDTA tubes shortly after collection (within 4 to 6 hours) favoring maximum sample integrity.
- "This is a key development milestone not just for Tethis but hopefully for liquid biopsy adoption" said Mr. Gian Martino Franchi, Chief Technology Officer of the company.
- "It's a first step towards true multi-analytical, standardized liquid biopsy tests involving all possible tumor content released in the bloodstream.